Skip to main content
Erschienen in:

09.07.2024 | Colorectal Cancer

Patient-Reported Outcomes in Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer After Pelvic Exenteration

verfasst von: Xu Lin, BS, Zhou Haiyang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Pelvic exenteration (PE) is often the only curative treatment option for selected locally advanced and locally recurrent colorectal cancer associated with significant morbidity. Open and laparoscopic approaches were accepted for this procedure.

Objective

This study aimed to examine the Chinese patient-reported outcomes (PROs) and health-related quality of life (HRQoL) after PE.

Methods

A total of 122 enrolled participants were asked to complete PROs at baseline and 1, 3, 6, 9 and 12 months after PE. PROs included seven symptoms from the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). The HRQoL was assessed using the Functional Assessment of Cancer Therapy-Colorectal (FACT-C).

Results

The overall postoperative complication rate was 41.0%. Patients experienced lower physical and functional well-being and FACT-C 1 month after surgery, then gradually recovered. The FACT-C score returned to baseline 9 months after surgery. Social and emotional well-being did not show signs of recovery until 6 months after the surgical procedure, and did not fully return to baseline until 12 months post-surgery. Symptom rates of insomnia, anxiety, discouragement, and sadness (composite score >0) did not improve significantly from baseline until 12 months after surgery.

Conclusions

PE is a feasible treatment choice for locally advanced primary and recurrent colorectal cancer. Social, psychological, and emotional recovery in the Chinese population after PE tends to be slower compared with the physical condition.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Winter DC, Walsh R, Lee G, Kiely D, O’Riordain MG, O’Sullivan GC. Local involvement of the urinary bladder in primary colorectal cancer: outcome with en bloc resection. Ann Surg Oncol. 2007;2:441–6.CrossRef Winter DC, Walsh R, Lee G, Kiely D, O’Riordain MG, O’Sullivan GC. Local involvement of the urinary bladder in primary colorectal cancer: outcome with en bloc resection. Ann Surg Oncol. 2007;2:441–6.CrossRef
2.
Zurück zum Zitat Rahbari NN, Ulrich AB, Bruckner T, et al. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: Is there still a chance for cure? Ann Surg. 2011;3:522–33.CrossRef Rahbari NN, Ulrich AB, Bruckner T, et al. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: Is there still a chance for cure? Ann Surg. 2011;3:522–33.CrossRef
3.
Zurück zum Zitat Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;2:177–83.CrossRef Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;2:177–83.CrossRef
4.
Zurück zum Zitat Platt E, Dovell G, Smolarek S. Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer. Tech Coloproctol. 2018;11:835–45.CrossRef Platt E, Dovell G, Smolarek S. Systematic review of outcomes following pelvic exenteration for the treatment of primary and recurrent locally advanced rectal cancer. Tech Coloproctol. 2018;11:835–45.CrossRef
5.
Zurück zum Zitat Harji DP, Griffiths B, Velikova G, Sagar PM, Brown J. Systematic review of health-related quality of life in patients undergoing pelvic exenteration. Eur J Surg Oncol. 2016;8:1132–45.CrossRef Harji DP, Griffiths B, Velikova G, Sagar PM, Brown J. Systematic review of health-related quality of life in patients undergoing pelvic exenteration. Eur J Surg Oncol. 2016;8:1132–45.CrossRef
6.
Zurück zum Zitat Bradley C, Johnston DLPT. Cochrane handbook for systematic reviews of interventions version 6.4. 2023. Bradley C, Johnston DLPT. Cochrane handbook for systematic reviews of interventions version 6.4. 2023.
7.
Zurück zum Zitat Rezk YA, Hurley KE, Carter J, et al. A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. Gynecol Oncol. 2013;2:191–7.CrossRef Rezk YA, Hurley KE, Carter J, et al. A prospective study of quality of life in patients undergoing pelvic exenteration: interim results. Gynecol Oncol. 2013;2:191–7.CrossRef
8.
Zurück zum Zitat Li L, Ma SQ, Tan XJ, Zhong S, Wu M. Pelvic exenteration for recurrent and persistent cervical cancer. Chinese Med J (Engl). 2018;131(13):1541–8.CrossRef Li L, Ma SQ, Tan XJ, Zhong S, Wu M. Pelvic exenteration for recurrent and persistent cervical cancer. Chinese Med J (Engl). 2018;131(13):1541–8.CrossRef
9.
Zurück zum Zitat Wu T, Wen L, Zhang J, et al. Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4B rectal cancer [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2019;1:59–65. Wu T, Wen L, Zhang J, et al. Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4B rectal cancer [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2019;1:59–65.
10.
Zurück zum Zitat Yuan H, Yao B, Li JT, et al. Observational study on perioperative outcomes of pelvic exenteration [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;3:260–7. Yuan H, Yao B, Li JT, et al. Observational study on perioperative outcomes of pelvic exenteration [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;3:260–7.
11.
Zurück zum Zitat Zhang Z, Zang R, Chen J. Pelvic exenteration of advanced gynecological malignacies: a report of 18 cases [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2000;5:288–90. Zhang Z, Zang R, Chen J. Pelvic exenteration of advanced gynecological malignacies: a report of 18 cases [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2000;5:288–90.
12.
Zurück zum Zitat Tang J, Liu J, Du B, et al. Short- and long-term outcomes of laparoscopic versus open pelvic exenteration for locally advanced rectal cancer: a single-center propensity score matching analysis. Tech Coloproctol. 2023;1:43–52.CrossRef Tang J, Liu J, Du B, et al. Short- and long-term outcomes of laparoscopic versus open pelvic exenteration for locally advanced rectal cancer: a single-center propensity score matching analysis. Tech Coloproctol. 2023;1:43–52.CrossRef
13.
Zurück zum Zitat He YJ, Zhou ZL, Qin QY, et al. Pelvic exenteration for late complications of radiation-induced pelvic injury: a preliminary study [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;10:940–6. He YJ, Zhou ZL, Qin QY, et al. Pelvic exenteration for late complications of radiation-induced pelvic injury: a preliminary study [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;10:940–6.
14.
Zurück zum Zitat Zhou MW, Li ZY, Gu XD, et al. Impact of surgical treatment for locally recurrent rectal cancer on the quality of Life of patients [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;4:352–8. Zhou MW, Li ZY, Gu XD, et al. Impact of surgical treatment for locally recurrent rectal cancer on the quality of Life of patients [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;4:352–8.
15.
Zurück zum Zitat Xishan W. Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 Edition) [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;26(1):16–26. Xishan W. Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 Edition) [in Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;26(1):16–26.
16.
Zurück zum Zitat Leaper DJ, Edmiston CE. World Health Organization: global guidelines for the prevention of surgical site infection. J Hosp Infect. 2017;95(2):135–6.PubMedCrossRef Leaper DJ, Edmiston CE. World Health Organization: global guidelines for the prevention of surgical site infection. J Hosp Infect. 2017;95(2):135–6.PubMedCrossRef
17.
Zurück zum Zitat Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) Hospital infection control practices advisory committee. Am J Infect Control. 1999;1999(20):247–80. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) Hospital infection control practices advisory committee. Am J Infect Control. 1999;1999(20):247–80.
18.
Zurück zum Zitat Yoo HJ, Kim JC, Eremenco S, Han OS. Quality of life in colorectal cancer patients with colectomy and the validation of the functional assessment of cancer therapy-colorectal (Fact-C), version 4. J Pain Symptom Manag. 2005;1:24–32.CrossRef Yoo HJ, Kim JC, Eremenco S, Han OS. Quality of life in colorectal cancer patients with colectomy and the validation of the functional assessment of cancer therapy-colorectal (Fact-C), version 4. J Pain Symptom Manag. 2005;1:24–32.CrossRef
19.
Zurück zum Zitat Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Out. 2003;1:1–7.CrossRef Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Out. 2003;1:1–7.CrossRef
20.
Zurück zum Zitat Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the functional assessment of cancer therapy-colorectal (Fact-C) quality of life instrument. Qual Life Res. 1999;3:181–95.CrossRef Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the functional assessment of cancer therapy-colorectal (Fact-C) quality of life instrument. Qual Life Res. 1999;3:181–95.CrossRef
21.
Zurück zum Zitat Ganesh V, Agarwal A, Popovic M, et al. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer. 2016;8:3661–8.CrossRef Ganesh V, Agarwal A, Popovic M, et al. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Support Care Cancer. 2016;8:3661–8.CrossRef
22.
Zurück zum Zitat Wong CK, Lam CL, Law WL, et al. Validity and reliability study on traditional chinese fact-C in chinese patients with colorectal neoplasm. J Eval Clin Pract. 2012;6:1186–95.CrossRef Wong CK, Lam CL, Law WL, et al. Validity and reliability study on traditional chinese fact-C in chinese patients with colorectal neoplasm. J Eval Clin Pract. 2012;6:1186–95.CrossRef
23.
Zurück zum Zitat National Cancer Institute. Patient-reported outcomes version of the common terminology criteria for adverse events. National Cancer Institute; 2023 National Cancer Institute. Patient-reported outcomes version of the common terminology criteria for adverse events. National Cancer Institute; 2023
24.
Zurück zum Zitat Basch E, Becker C, Rogak LJ, et al. Composite grading algorithm for the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials. 2021;1:104–14.CrossRef Basch E, Becker C, Rogak LJ, et al. Composite grading algorithm for the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Clin Trials. 2021;1:104–14.CrossRef
25.
Zurück zum Zitat Basch E, Dueck AC, Mitchell SA, et al. Patient-Reported outcomes during and after treatment for locally advanced rectal cancer in the prospect trial (alliance N1048). J Clin Oncol. 2023;21:3724–34.CrossRef Basch E, Dueck AC, Mitchell SA, et al. Patient-Reported outcomes during and after treatment for locally advanced rectal cancer in the prospect trial (alliance N1048). J Clin Oncol. 2023;21:3724–34.CrossRef
26.
Zurück zum Zitat Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer. 2014;1:156–64.CrossRef Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer. 2014;1:156–64.CrossRef
27.
Zurück zum Zitat Kelly M, Winter D, Ryan É, Sammour T, Kroon H. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann Surg. 2019;270(5):899–905.CrossRef Kelly M, Winter D, Ryan É, Sammour T, Kroon H. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann Surg. 2019;270(5):899–905.CrossRef
28.
Zurück zum Zitat Khan O, Patsouras D, Ravindraanandan M, et al. Total pelvic exenteration for locally advanced and recurrent rectal cancer: urological outcomes and adverse events. Eur Urol Focus. 2021;3:638–43.CrossRef Khan O, Patsouras D, Ravindraanandan M, et al. Total pelvic exenteration for locally advanced and recurrent rectal cancer: urological outcomes and adverse events. Eur Urol Focus. 2021;3:638–43.CrossRef
29.
Zurück zum Zitat Clark DG, Daniel WW, Brunschwig A. Intestinal fistulas following pelvic exenteration. Am J Obstet Gynecol. 1962;84:187–91.PubMedCrossRef Clark DG, Daniel WW, Brunschwig A. Intestinal fistulas following pelvic exenteration. Am J Obstet Gynecol. 1962;84:187–91.PubMedCrossRef
30.
Zurück zum Zitat Sutton PA, Brown K, Ebrahimi N, Solomon MJ, Austin K, Lee PJ. Long-term surgical complications following pelvic exenteration: operative management of the empty pelvis syndrome. Colorectal Dis. 2022;12:1491–7.CrossRef Sutton PA, Brown K, Ebrahimi N, Solomon MJ, Austin K, Lee PJ. Long-term surgical complications following pelvic exenteration: operative management of the empty pelvis syndrome. Colorectal Dis. 2022;12:1491–7.CrossRef
31.
Zurück zum Zitat Chokshi RJ, Kuhrt MP, Arrese D, Martin EJ. Reconstruction of total pelvic exenteration defects with rectus abdominus myocutaneous flaps versus primary closure. Am J Surg. 2013;1:64–70.CrossRef Chokshi RJ, Kuhrt MP, Arrese D, Martin EJ. Reconstruction of total pelvic exenteration defects with rectus abdominus myocutaneous flaps versus primary closure. Am J Surg. 2013;1:64–70.CrossRef
32.
Zurück zum Zitat Lee P, Tan WJ, Brown K, Solomon MJ. Addressing the empty pelvic syndrome following total pelvic exenteration: Does mesh reconstruction help? Colorectal Dis. 2019;3:365–9.CrossRef Lee P, Tan WJ, Brown K, Solomon MJ. Addressing the empty pelvic syndrome following total pelvic exenteration: Does mesh reconstruction help? Colorectal Dis. 2019;3:365–9.CrossRef
33.
Zurück zum Zitat Miyamoto Y, Akiyama T, Sakamoto Y, et al. Omental flap after pelvic exenteration for pelvic cancer. Surg Today. 2016;12:1471–5.CrossRef Miyamoto Y, Akiyama T, Sakamoto Y, et al. Omental flap after pelvic exenteration for pelvic cancer. Surg Today. 2016;12:1471–5.CrossRef
34.
Zurück zum Zitat Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum. 2008;3:284–91.CrossRef Heriot AG, Byrne CM, Lee P, et al. Extended radical resection: the choice for locally recurrent rectal cancer. Dis Colon Rectum. 2008;3:284–91.CrossRef
35.
Zurück zum Zitat Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum. 2004;10:1599–606.CrossRef Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum. 2004;10:1599–606.CrossRef
36.
Zurück zum Zitat Yang HY, Park SC, Hyun JH, Seo HK, Oh JH. Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer. Ann Surg Treat Res. 2015;3:131–7.CrossRef Yang HY, Park SC, Hyun JH, Seo HK, Oh JH. Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer. Ann Surg Treat Res. 2015;3:131–7.CrossRef
37.
Zurück zum Zitat PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Brit J Surg. 2018;6:650–7.CrossRef PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Brit J Surg. 2018;6:650–7.CrossRef
38.
Zurück zum Zitat Collaborative PelvEx. Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer. BJS Open. 2019;4:516–20.CrossRef Collaborative PelvEx. Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer. BJS Open. 2019;4:516–20.CrossRef
39.
Zurück zum Zitat Collaborative PelvEx. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg. 2019;269(2):315–21.CrossRef Collaborative PelvEx. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg. 2019;269(2):315–21.CrossRef
40.
Zurück zum Zitat Targarona EM, Balague C, Pernas JC, et al. Can we predict immediate outcome after laparoscopic rectal surgery? Multivariate analysis of clinical, anatomic, and pathologic features after 3-dimensional reconstruction of the pelvic anatomy. Ann Surg. 2008;4:642–9.CrossRef Targarona EM, Balague C, Pernas JC, et al. Can we predict immediate outcome after laparoscopic rectal surgery? Multivariate analysis of clinical, anatomic, and pathologic features after 3-dimensional reconstruction of the pelvic anatomy. Ann Surg. 2008;4:642–9.CrossRef
41.
Zurück zum Zitat Drami I, Lord AC, Sarmah P, et al. Preoperative assessment and optimisation for pelvic exenteration in locally advanced and recurrent rectal cancer: a review. Eur J Surg Oncol. 2022;11:2250–7.CrossRef Drami I, Lord AC, Sarmah P, et al. Preoperative assessment and optimisation for pelvic exenteration in locally advanced and recurrent rectal cancer: a review. Eur J Surg Oncol. 2022;11:2250–7.CrossRef
42.
Zurück zum Zitat van Ramshorst GH, O’Shannassy S, Brown WE, Kench JG, Solomon MJ. A qualitative study of the development of a multidisciplinary case conference review methodology to reduce involved margins in pelvic exenteration surgery for recurrent rectal cancer. Colorectal Dis. 2018;11:1004–13.CrossRef van Ramshorst GH, O’Shannassy S, Brown WE, Kench JG, Solomon MJ. A qualitative study of the development of a multidisciplinary case conference review methodology to reduce involved margins in pelvic exenteration surgery for recurrent rectal cancer. Colorectal Dis. 2018;11:1004–13.CrossRef
43.
Zurück zum Zitat Collaborative PelvEx. Minimum standards of pelvic exenterative practice: pelvex collaborative guideline. Brit J Surg. 2022;12:1251–63.CrossRef Collaborative PelvEx. Minimum standards of pelvic exenterative practice: pelvex collaborative guideline. Brit J Surg. 2022;12:1251–63.CrossRef
44.
Zurück zum Zitat Rausa E, Kelly ME, Bonavina L, O’Connell PR, Winter DC. A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer. Colorectal Dis. 2017;5:430–6.CrossRef Rausa E, Kelly ME, Bonavina L, O’Connell PR, Winter DC. A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer. Colorectal Dis. 2017;5:430–6.CrossRef
45.
Zurück zum Zitat McKigney N, Houston F, Ross E, Velikova G, Brown J, Harji DP. Systematic review of patient-reported outcome measures in locally recurrent rectal cancer. Ann Surg Oncol. 2023;7:3969–86.CrossRef McKigney N, Houston F, Ross E, Velikova G, Brown J, Harji DP. Systematic review of patient-reported outcome measures in locally recurrent rectal cancer. Ann Surg Oncol. 2023;7:3969–86.CrossRef
46.
Zurück zum Zitat Radwan RW, Codd RJ, Wright M, et al. Quality-of-life outcomes following pelvic exenteration for primary rectal cancer. Br J Surg. 2015;12:1574–80.CrossRef Radwan RW, Codd RJ, Wright M, et al. Quality-of-life outcomes following pelvic exenteration for primary rectal cancer. Br J Surg. 2015;12:1574–80.CrossRef
47.
Zurück zum Zitat Quyn AJ, Austin KK, Young JM, et al. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: overall survival and quality of life. Eur J Surg Oncol. 2016;6:823–8.CrossRef Quyn AJ, Austin KK, Young JM, et al. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: overall survival and quality of life. Eur J Surg Oncol. 2016;6:823–8.CrossRef
48.
Zurück zum Zitat Krischak MK, Hayden JP, Krughoff K, et al. Patient-reported and physiologic outcomes following pelvic exenteration for non-repairable radiated rectourethral fistula. Urology. 2022;166:257–63.PubMedCrossRef Krischak MK, Hayden JP, Krughoff K, et al. Patient-reported and physiologic outcomes following pelvic exenteration for non-repairable radiated rectourethral fistula. Urology. 2022;166:257–63.PubMedCrossRef
49.
Zurück zum Zitat Quyn AJ, Solomon MJ, Lee PM, Badgery-Parker T, Masya LM, Young JM. Palliative pelvic exenteration: clinical outcomes and quality of life. Dis Colon Rectum. 2016;11:1005–10.CrossRef Quyn AJ, Solomon MJ, Lee PM, Badgery-Parker T, Masya LM, Young JM. Palliative pelvic exenteration: clinical outcomes and quality of life. Dis Colon Rectum. 2016;11:1005–10.CrossRef
50.
Zurück zum Zitat Kroon HM, Dudi-Venkata NN, Bedrikovetski S, et al. Palliative pelvic exenteration: a systematic review of patient-centered outcomes. Eur J Surg Oncol. 2019;10:1787–95.CrossRef Kroon HM, Dudi-Venkata NN, Bedrikovetski S, et al. Palliative pelvic exenteration: a systematic review of patient-centered outcomes. Eur J Surg Oncol. 2019;10:1787–95.CrossRef
51.
Zurück zum Zitat Alahmadi R, Steffens D, Solomon MJ, Lee PJ, Austin K, Koh CE. Elderly patients have better quality of life but worse survival following pelvic exenteration: a 25-year single-center experience. Ann Surg Oncol. 2021;9:5226–35.CrossRef Alahmadi R, Steffens D, Solomon MJ, Lee PJ, Austin K, Koh CE. Elderly patients have better quality of life but worse survival following pelvic exenteration: a 25-year single-center experience. Ann Surg Oncol. 2021;9:5226–35.CrossRef
52.
Zurück zum Zitat Roos E, Degraeff A, Vaneijkeren M, Boon T, Heintz A. Quality of life after pelvic exenteration. Gynecol Oncol. 2004;3:610–4.CrossRef Roos E, Degraeff A, Vaneijkeren M, Boon T, Heintz A. Quality of life after pelvic exenteration. Gynecol Oncol. 2004;3:610–4.CrossRef
Metadaten
Titel
Patient-Reported Outcomes in Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer After Pelvic Exenteration
verfasst von
Xu Lin, BS
Zhou Haiyang, MD
Publikationsdatum
09.07.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15722-x

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.